London School of Hygiene and Tropical Medicine

lshtm.ac.uk

Total trials

296

Active

18

Phase 3

86

Total enrollment

4,749,932

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Gardasil® HPV vaccine2
Pneumococcal conjugate vaccine1
Tranexamic Acid 500 MG2
Tranexamic Acid6
bivalent HPV vaccine1
nonavalent HPV vaccine1
PvSeroTAT1
R21Matrix M1
Amoxicillin2
Linezolid1
Benzathine Penicillin G1
Sulfadoxine pyrimethamine3
prednisolone4
Methotrexate1

Next readouts

  • 2020-01-15
  • 2024-12-31
  • 2025-01-18
  • 2025-06
  • 2025-08
  • 2025-09
  • 2025-09-01
  • 2025-11
  • 2026-12-31
  • 2027-03-31

Top conditions

  • Malaria93
  • Anaemia12
  • Diarrhea10
  • Anemia9
  • Malaria,Falciparum8
  • Pregnancy8
  • HIV Infections8
  • HIV7

Frequently asked questions about London School of Hygiene and Tropical Medicine

How many clinical trials does London School of Hygiene and Tropical Medicine have on ClinicalTrials.gov?
London School of Hygiene and Tropical Medicine is listed as the lead sponsor on 296 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
How many of London School of Hygiene and Tropical Medicine's trials are in Phase 3?
86 of London School of Hygiene and Tropical Medicine's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does London School of Hygiene and Tropical Medicine focus on?
London School of Hygiene and Tropical Medicine's most-studied conditions on ClinicalTrials.gov are Malaria, Anaemia, Diarrhea, Anemia, Malaria,Falciparum.
When are London School of Hygiene and Tropical Medicine's next clinical trial readouts?
London School of Hygiene and Tropical Medicine has 10 upcoming primary-completion readouts tracked here; the soonest is “A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls”, expected around 2020-01-15.